论文部分内容阅读
供受者间HLA差异越大,移植物抗肿瘤效应越明显,异基因移植后复发的可能性就越小。但供受者间HLA不相合的移植会增加移植物抗宿主病(graft-versus-host disease,GVHD)风险和非复发死亡率。有针对
The greater the difference between donor and recipient HLA, the more obvious the anti-tumor effect of the graft, and the less the possibility of recurrence after allogeneic transplantation. However, donor-to-recipient HLA mismatch transplants increase the risk of graft-versus-host disease (GVHD) and non-recurrent mortality. Targeted